Apr 21, 2014

CardioCell Scientific Advisory Board Chair Joins “Novel Technologies in Stem Cell Research” Panel at the 2014 Stem Cell Summit

CAMBRIDGE, MASS. – STEM CELL SUMMIT 2014 – April 21, 2014 – CardioCell announces a presentation by noted cardiologist Dr. Stephen Epstein, the company’s Scientific Advisory Board chair, as well as director, translational and vascular biology research at MedStar Heart Institute and clinical professor of medicine at Georgetown University. In the talk, “Angiomyogenesis and Stem Cell Therapy: New Strategies to Surmount Obstacles to Success,” Dr. Epstein offers new therapy concepts leveraging data derived from CardioCell, whose novel method of growing stem cells under chronic hypoxic conditions is yielding promising clinical-trial results.

Details:	Dr. Stephen Epstein’s talk covers “New Strategies to Surmount Obstacles to Success for Angiomyogenesis and Stem Cell Therapy.” He discusses: potential reasons why the use of adult stem cells to treat cardiovascular disease has to date produced, at best, less-than-robust results from large, randomized controlled studies. the important effects the oxygen environment under which MSCs (mesenchymal stem cells) are grown has on MSC function and on the unique characteristics of allogeneic MSCs grown under chronic hypoxic conditions. data that indicate such cells more effectively home to and engraft in ischemic tissue – even when administered intravenously – and have characteristics (migration, cytokine secretory patterns) that raise the likelihood they will have a more robust therapeutic effect than MSCs grown under normoxic conditions.
When:	Thurs., April 24, 2014, at 11:20 a.m. Eastern time
Where:	Stem Cell Summit 2014 – 3rd Stem Cell Commercialization & Partnering Conference Hyatt Regency in Cambridge, Mass. Hayme Saloman Room
Contact:	Kimberly Stoddard, kimberly@townsendteam.com, (415) 806-5793

About CardioCell, LLC

Founded in San Diego, Calif., in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the former Soviet Union, Europe and the United States. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.